Research Progress Concerning MA Methylation and Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Sep 30

PMID 34589154

Citations 9

Authors

Yang Zhou

Jie Yang

Zheng Tian

Jing Zeng

Weigan Shen

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (mA) methylation is a type of methylation modification on RNA molecules, which was first discovered in 1974, and has become a hot topic in life science in recent years. mA modification is an epigenetic regulation similar to DNA and histone modification and is dynamically reversible in mammalian cells. This chemical marker of RNA is produced by mA 'writers' (methylase) and can be degraded by mA 'erasers' (demethylase). Methylated reading protein is the 'reader', that can recognize the mRNA containing mA and regulate the expression of downstream genes accordingly. mA methylation is involved in all stages of the RNA life cycle, including RNA processing, nuclear export, translation and regulation of RNA degradation, indicating that mA plays a crucial role in RNA metabolism. Recent studies have shown that mA modification is a complicated regulatory network in different cell lines, tissues and spatio-temporal models, and mA methylation is associated with the occurrence and development of tumors. The present review describes the regulatory mechanism and physiological functions of mA methylation, and its research progress in several types of human tumor, to provide novel approaches for early diagnosis and targeted treatment of cancer.

Citing Articles

Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).

Pan J, Tong F, Ren N, Ren L, Yang Y, Gao F Oncol Rep. 2024; 51(6).

PMID: 38757383 PMC: 11110010. DOI: 10.3892/or.2024.8747.

RNA m6A methylation regulators in liver cancer.

Xu Q, Ren N, Ren L, Yang Y, Pan J, Shang H Cancer Cell Int. 2024; 24(1):1.

PMID: 38166832 PMC: 10763310. DOI: 10.1186/s12935-023-03197-x.

BIRC5 facilitates cisplatin-chemoresistance in a mA-dependent manner in ovarian cancer.

Fan Y, Pan Y, Jia L, Gu S, Liu B, Mei Z Cancer Med. 2023; 13(1):e6811.

PMID: 38112021 PMC: 10807614. DOI: 10.1002/cam4.6811.

METTL16 in human diseases: What should we do next?.

Zhang H, Yin M, Huang H, Zhao G, Lu M Open Med (Wars). 2023; 18(1):20230856.

PMID: 38045858 PMC: 10693013. DOI: 10.1515/med-2023-0856.

Underexplored reciprocity between genome-wide methylation status and long non-coding RNA expression reflected in breast cancer research: potential impacts for the disease management in the framework of 3P medicine.

Kapinova A, Mazurakova A, Halasova E, Dankova Z, Busselberg D, Costigliola V EPMA J. 2023; 14(2):249-273.

PMID: 37275549 PMC: 10236066. DOI: 10.1007/s13167-023-00323-7.

References

Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z . The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021; 6(1):74. PMC: 7897327. DOI: 10.1038/s41392-020-00450-x. View

Gaudet M, Yang H, Gonzalez Bosquet J, Healey C, Ahmed S, Dunning A . No association between FTO or HHEX and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):2106-9. PMC: 2919629. DOI: 10.1158/1055-9965.EPI-10-0515. View

Zhang Y, Zhang S, Liu L, Liu H, Zhang L, Cui X . Spatially Enhanced Differential RNA Methylation Analysis from Affinity-Based Sequencing Data with Hidden Markov Model. Biomed Res Int. 2015; 2015:852070. PMC: 4537718. DOI: 10.1155/2015/852070. View

Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X . The mechanism of mA methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis. 2020; 11(11):969. PMC: 7658972. DOI: 10.1038/s41419-020-03148-8. View

Tian R, Zhang S, Sun D, Bei C, Li D, Zheng C . M6A Demethylase FTO Plays a Tumor Suppressor Role in Thyroid Cancer. DNA Cell Biol. 2020; . DOI: 10.1089/dna.2020.5956. View

Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J . RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016; 376(1):34-42. DOI: 10.1016/j.canlet.2016.02.022. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

Xu C, Liu K, Tempel W, Demetriades M, Aik W, Schofield C . Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N6-methyladenosine RNA demethylation. J Biol Chem. 2014; 289(25):17299-311. PMC: 4067165. DOI: 10.1074/jbc.M114.550350. View

10.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

11.

Detich N, Hamm S, Just G, Knox J, Szyf M . The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. J Biol Chem. 2003; 278(23):20812-20. DOI: 10.1074/jbc.M211813200. View

12.

Chen J, Zhang Y, Huang C, Shen H, Sun B, Cheng X . mA Regulates Neurogenesis and Neuronal Development by Modulating Histone Methyltransferase Ezh2. Genomics Proteomics Bioinformatics. 2019; 17(2):154-168. PMC: 6620265. DOI: 10.1016/j.gpb.2018.12.007. View

13.

Du C, Lv C, Feng Y, Yu S . Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 2020; 39(1):223. PMC: 7576758. DOI: 10.1186/s13046-020-01735-3. View

14.

Lin S, Liu J, Jiang W, Wang P, Sun C, Wang X . METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells. Open Med (Wars). 2019; 14:25-31. PMC: 6419388. DOI: 10.1515/med-2019-0005. View

15.

Wang M, Liu J, Zhao Y, He R, Xu X, Guo X . Upregulation of METTL14 mediates the elevation of PERP mRNA N adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020; 19(1):130. PMC: 7446161. DOI: 10.1186/s12943-020-01249-8. View

16.

Ke S, Alemu E, Mertens C, Gantman E, Fak J, Mele A . A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev. 2015; 29(19):2037-53. PMC: 4604345. DOI: 10.1101/gad.269415.115. View

17.

Enane F, Saunthararajah Y, Korc M . Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018; 9(9):912. PMC: 6127320. DOI: 10.1038/s41419-018-0919-9. View

18.

Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C . N-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020; 11(10):836. PMC: 7547657. DOI: 10.1038/s41419-020-03049-w. View

19.

Liu J, Eckert M, Harada B, Liu S, Lu Z, Yu K . mA mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018; 20(9):1074-1083. PMC: 6245953. DOI: 10.1038/s41556-018-0174-4. View

20.

Shi H, Wei J, He C . Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Mol Cell. 2019; 74(4):640-650. PMC: 6527355. DOI: 10.1016/j.molcel.2019.04.025. View